Chronic obstructive pulmonary disease exacerbation frequency and serum IgG levels - 28/02/18
Doi : 10.1016/j.jaci.2017.09.036
Juthaporn Cowan, MD, PhD a, b, c 
, Sunita Mulpuru, MD, MSc a, b, Gonzalo Alvarez, MD, MPH a, b, d, Vicente Corrales-Medina, MD, MSc a, b, d, Donald W. Cameron, MD a, b, c, d
, Sunita Mulpuru, MD, MSc a, b, Gonzalo Alvarez, MD, MPH a, b, d, Vicente Corrales-Medina, MD, MSc a, b, d, Donald W. Cameron, MD a, b, c, d a Department of Medicine, University of Ottawa at The Ottawa Hospital, Ottawa, Ontario, Canada
b Clinical Epidemiology Program, The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
c Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada
d School of Epidemiology, Public Health and Preventative Medicine, University of Ottawa, Ottawa, Ontario, Canada
Le texte complet de cet article est disponible en PDF.
| Disclosure of potential conflict of interest: J. Cowan personally received consultancy fees from Shire Canada and grants and travel reimbursement from CSL Behring and Grifols. S. Mulpuru personally received payment for lectures from Astrazenca. D. W. Cameron's institution received board membership and grants from CSL Behring and Grifols for other works; he is supported by a salary award from the Department of Medicine University of Ottawa. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2017
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 141 - N° 2
P. 830-831 - février 2018 Retour au numéro
Article précédent
- Reply
- Hooman Mirzakhani, Scott T. Weiss, Augusto A. Litonjua
- Reply
- Fernando Sergio Leitao Filho, Seung Won Ra, Andre Mattman, Robert S. Schellenberg, Don D. Sin
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?